Treatment outcome for other cytogenetic groups after exclusion of patients with t(8;21), inv(16)/t(16;16), t(9;11), and complex ≥3 karyotype
| Cytogenetic group . | No. of patients . | No. of CRs (%) . | P8-150 . | 5-y CIR (SE) . | P8-150 . | Median OS, y . | % 5-y OS (95% CI) . | P8-150 . |
|---|---|---|---|---|---|---|---|---|
| Normal | 582 | 395 (68) | NA | 0.66 (0.01) | NA | 1.3 | 24 (20-27) | NA |
| del(9q)8-151 | 13 | 12 (92) | .07 | 0.58 (0.15) | .55 | >4.5 | 54 (29-77) | .01 |
| +21 | 11 | 8 (73) | .77 | 0.88 | .002 | 1.1 | 18 (6-42) | .96 |
| −Y | 22 | 14 (64) | .82 | 0.79 | .27 | 0.7 | 23 (11-42) | .40 |
| +8 sole | 41 | 25 (61) | .39 | 0.77 (0.09) | .54 | 1.0 | 12 (5-27) | .049 |
| +13 | 17 | 10 (59) | .60 | 0.70 (0.16) | .98 | 1.0 | 6 (2-19) | .22 |
| del(20q) | 7 | 4 (57) | .69 | ND | ND | 0.3 | 29 (10-58) | .41 |
| Loss of 7q | 7 | 4 (57) | .69 | ND | ND | 1.0 | 14 (4-40) | .62 |
| t(6;11) | 7 | 4 (57) | .69 | ND | ND | 0.3 | 0 | .002 |
| +8 with 1 other abnormality8-152 | 26 | 13 (50) | .09 | 0.77 (0.13) | .050 | 0.5 | 8 (3-20) | .002 |
| t(11;19)(q23;p13.1) | 6 | 3 (50) | .39 | ND | ND | 0.6 | 0 | .03 |
| −7 | 21 | 10 (48) | .06 | 0.80 (0.17) | .02 | 0.6 | 0 | <.001 |
| +11 | 13 | 6 (46) | .13 | 0.83 (0.20) | .74 | 0.7 | 8 (2-24) | .24 |
| del(11q) | 7 | 3 (43) | .22 | ND | ND | 0.7 | 14 (4-40) | .46 |
| del(5q) | 5 | 2 (40) | .34 | ND | ND | >3.3 | 40 (15-72) | .23 |
| t(6;9) | 8 | 3 (38) | .12 | ND | ND | 0.9 | 0 | .03 |
| abn(12p) | 7 | 2 (29) | .04 | ND | ND | 0.4 | 14 (4-40) | .53 |
| inv(3) or t(3;3) | 8 | 1 (13) | .002 | ND | ND | 0.2 | 0 | .007 |
| Cytogenetic group . | No. of patients . | No. of CRs (%) . | P8-150 . | 5-y CIR (SE) . | P8-150 . | Median OS, y . | % 5-y OS (95% CI) . | P8-150 . |
|---|---|---|---|---|---|---|---|---|
| Normal | 582 | 395 (68) | NA | 0.66 (0.01) | NA | 1.3 | 24 (20-27) | NA |
| del(9q)8-151 | 13 | 12 (92) | .07 | 0.58 (0.15) | .55 | >4.5 | 54 (29-77) | .01 |
| +21 | 11 | 8 (73) | .77 | 0.88 | .002 | 1.1 | 18 (6-42) | .96 |
| −Y | 22 | 14 (64) | .82 | 0.79 | .27 | 0.7 | 23 (11-42) | .40 |
| +8 sole | 41 | 25 (61) | .39 | 0.77 (0.09) | .54 | 1.0 | 12 (5-27) | .049 |
| +13 | 17 | 10 (59) | .60 | 0.70 (0.16) | .98 | 1.0 | 6 (2-19) | .22 |
| del(20q) | 7 | 4 (57) | .69 | ND | ND | 0.3 | 29 (10-58) | .41 |
| Loss of 7q | 7 | 4 (57) | .69 | ND | ND | 1.0 | 14 (4-40) | .62 |
| t(6;11) | 7 | 4 (57) | .69 | ND | ND | 0.3 | 0 | .002 |
| +8 with 1 other abnormality8-152 | 26 | 13 (50) | .09 | 0.77 (0.13) | .050 | 0.5 | 8 (3-20) | .002 |
| t(11;19)(q23;p13.1) | 6 | 3 (50) | .39 | ND | ND | 0.6 | 0 | .03 |
| −7 | 21 | 10 (48) | .06 | 0.80 (0.17) | .02 | 0.6 | 0 | <.001 |
| +11 | 13 | 6 (46) | .13 | 0.83 (0.20) | .74 | 0.7 | 8 (2-24) | .24 |
| del(11q) | 7 | 3 (43) | .22 | ND | ND | 0.7 | 14 (4-40) | .46 |
| del(5q) | 5 | 2 (40) | .34 | ND | ND | >3.3 | 40 (15-72) | .23 |
| t(6;9) | 8 | 3 (38) | .12 | ND | ND | 0.9 | 0 | .03 |
| abn(12p) | 7 | 2 (29) | .04 | ND | ND | 0.4 | 14 (4-40) | .53 |
| inv(3) or t(3;3) | 8 | 1 (13) | .002 | ND | ND | 0.2 | 0 | .007 |
Abbreviations are explained in the footnote to Table5.
For comparison of abnormality with normal cytogenetics.
Six of the 13 patients with del(9q) underwent SCT off-protocol. For the remaining 7 patients who did not receive SCT, 5-year CIR (SE) was 0.67 (0.05), P = .96, median OS 1.5 years, and probability of 5-year OS 29% (95% CI, 10%-58%), P = .39. Thus, the OS of AML patients with del(9q) not undergoing transplantation is not significantly different from that of the normal group.
An abnormality accompanying +8 is other than t(8;21), t(9;11), and inv(16) or t(16;16).